OM
Opaleye Management Portfolio holdings
AUM
$494M
This Quarter Return
+4.61%
1 Year Return
+68.17%
3 Year Return
+608.37%
5 Year Return
+807.76%
10 Year Return
+24,567.29%
AUM
$418M
AUM Growth
+$418M
(+25%)
Cap. Flow
+$102M
Cap. Flow
% of AUM
24.46%
Top 10 Holdings %
Top 10 Hldgs %
66.46%
Holding
52
New
11
Increased
13
Reduced
15
Closed
5
Top Buys
| 1 |
SLRN
ACELYRIN
SLRN
|
$86.9M |
| 2 |
Geron
GERN
|
$7.54M |
| 3 |
CBAY
Cymabay Therapeutics
CBAY
|
$6.21M |
| 4 |
Acadia Pharmaceuticals
ACAD
|
$5.2M |
| 5 |
Intellia Therapeutics
NTLA
|
$4.89M |
Top Sells
| 1 |
Arcutis Biotherapeutics
ARQT
|
$5.52M |
| 2 |
TELA Bio
TELA
|
$4.99M |
| 3 |
Phathom Pharmaceuticals
PHAT
|
$3.54M |
| 4 |
JNCE
Jounce Therapeutics, Inc. Common Stock
JNCE
|
$3.03M |
| 5 |
Cytokinetics
CYTK
|
$2.53M |
Sector Composition
| 1 | Healthcare | 98.38% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
SLRN
1
DELISTED
ACELYRIN
SLRN
| $86.9M | 20.79% | +4,158,638 | New | +$86.9M |
|
2
Harrow
HROW
$1.44B
| $71.9M | 17.19% | 3,775,000 | – | – |
|
3
Ocular Therapeutix
OCUL
$2.12B
| $29.8M | 7.13% | 5,780,000 -325,900 | -5% | -$1.68M |
|
|
4
TELA Bio
TELA
$70.5M
| $16M | 3.83% | 1,580,000 -492,813 | -24% | -$4.99M |
|
5
Crinetics Pharmaceuticals
CRNX
$2.92B
| $15.2M | 3.64% | 845,000 +59,206 | +8% | +$1.07M |
|
6
Keros Therapeutics
KROS
$618M
| $14.2M | 3.39% | 352,650 +114,650 | +48% | +$4.61M |
|
7
Biohaven
BHVN
$1.63B
| $12.9M | 3.09% | 540,000 | – | – |
|
8
Rhythm Pharmaceuticals
RYTM
$6.85B
| $12.1M | 2.9% | 735,000 | – | – |
|
9
IDEAYA Biosciences
IDYA
$2.15B
| $9.75M | 2.33% | 415,000 +72,000 | +21% | +$1.69M |
|
|
MOR
10
DELISTED
MorphoSys AG American Depositary Shares
MOR
| $9.03M | 2.16% | 1,209,380 +15,380 | +1% | +$115K |
|
11
Vaxcyte
PCVX
$4B
| $8.84M | 2.11% | 177,000 | – | – |
|
12
Eton Pharmaceutcials
ETON
$464M
| $7.97M | 1.91% | 2,285,000 +100,000 | +5% | +$349K |
|
|
13
Geron
GERN
$893M
| $7.54M | 1.8% | +2,350,000 | New | +$7.54M |
|
|
MRNS
14
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
| $6.79M | 1.62% | 625,000 -140,000 | -18% | -$1.52M |
|
15
KalVista Pharmaceuticals
KALV
$678M
| $6.48M | 1.55% | 720,000 -203,200 | -22% | -$1.83M |
|
16
Protara Therapeutics
TARA
$120M
| $6.44M | 1.54% | 2,692,594 | – | – |
|
17
Edgewise Therapeutics
EWTX
$1.51B
| $6.32M | 1.51% | 815,000 +65,000 | +9% | +$504K |
|
|
CBAY
18
DELISTED
Cymabay Therapeutics
CBAY
| $6.21M | 1.48% | +566,700 | New | +$6.21M |
|
19
UroGen Pharma
URGN
$900M
| $5.9M | 1.41% | 570,000 +65,000 | +13% | +$673K |
|
20
Theravance Biopharma
TBPH
$699M
| $5.63M | 1.35% | 543,500 -2,804 | -0.5% | -$29K |
|
|
THRX
21
DELISTED
Theseus Pharmaceuticals, Inc. Common Stock
THRX
| $5.57M | 1.33% | 597,500 +109,400 | +22% | +$1.02M |
|
|
22
Acadia Pharmaceuticals
ACAD
$4.38B
| $5.2M | 1.24% | +217,000 | New | +$5.2M |
|
|
23
Intellia Therapeutics
NTLA
$1.22B
| $4.89M | 1.17% | +120,000 | New | +$4.89M |
|
24
Liquidia Corp
LQDA
$2.38B
| $4.48M | 1.07% | 570,700 -4,500 | -0.8% | -$35.3K |
|
25
Larimar Therapeutics
LRMR
$310M
| $4.35M | 1.04% | 1,390,000 -11,000 | -0.8% | -$34.4K |
|